



Vivimed

Investor Release

**Strides Vivimed JV receives approval for Albendazole Tablets**

**Second generic approval by US FDA for Albendazole Tablets Product to be launched immediately**

**Hyderabad, India, December 12, 2018** – Vivimed Labs Limited (Vivimed) today announced that its 50:50 JV Strides Vivimed Pte. Ltd, Singapore has received approval for Albendazole Tablets USP 200mg from the United States Food & Drug Administration (US FDA). This is the second generic approval for the product.



Vivimed

**Safe Harbour**

This release contains "forward looking statements" including, but without limitation, statements regarding the company's future performance, financial condition, and business prospects. These statements are based on the company's current expectations and assumptions, which are subject to change. The company does not intend to update these statements unless required by law.